Vyleesi is a Subcutaneous Injection in the Human Prescription Drug category. It is labeled and distributed by Palatin Technologies. The primary component is Bremelanotide Acetate.
| Product ID | 80064-141_2935c1f6-2000-47a2-aec9-43589ce521de | 
| NDC | 80064-141 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | Vyleesi | 
| Generic Name | Bremelanotide | 
| Dosage Form | Injection | 
| Route of Administration | SUBCUTANEOUS | 
| Marketing Start Date | 2019-06-21 | 
| Marketing Category | NDA / NDA | 
| Application Number | NDA210557 | 
| Labeler Name | Palatin Technologies | 
| Substance Name | BREMELANOTIDE ACETATE | 
| Active Ingredient Strength | 2 mg/.3mL | 
| NDC Exclude Flag | N | 
| Listing Certified Through | 2021-12-31 | 
| Marketing Start Date | 2019-06-21 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| NDC | Brand Name | Generic Name | 
|---|---|---|
| 64011-701 | Vyleesi | bremelanotide | 
| 80064-141 | Vyleesi | bremelanotide | 
Mark Image Registration | Serial  | Company  Trademark Application Date  | 
|---|---|
![]() VYLEESI  87665906  5897765 Live/Registered  | 
        AMAG Pharmaceuticals, Inc.  2017-10-31  |